Massachusetts Financial Services’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-494,497
| Closed | -$630K | – | 913 |
|
|
2024
Q4 | $630K | Sell |
494,497
-55,033
| -10% | -$70.2K | ﹤0.01% | 834 |
|
|
2024
Q3 | $1.14M | Buy |
549,530
+27,155
| +5% | +$56.2K | ﹤0.01% | 787 |
|
|
2024
Q2 | $1.99M | Buy |
522,375
+14,226
| +3% | +$54.2K | ﹤0.01% | 747 |
|
|
2024
Q1 | $2.41M | Sell |
508,149
-2,600
| -0.5% | -$12.3K | ﹤0.01% | 718 |
|
|
2023
Q4 | $2.18M | Buy |
510,749
+470
| +0.1% | +$2.01K | ﹤0.01% | 717 |
|
|
2023
Q3 | $1.58M | Buy |
510,279
+889
| +0.2% | +$2.75K | ﹤0.01% | 740 |
|
|
2023
Q2 | $2.29M | Sell |
509,390
-5,158
| -1% | -$23.2K | ﹤0.01% | 692 |
|
|
2023
Q1 | $2.93M | Sell |
514,548
-423
| -0.1% | -$2.41K | ﹤0.01% | 682 |
|
|
2022
Q4 | $3.11M | Buy |
514,971
+1,678
| +0.3% | +$10.1K | ﹤0.01% | 686 |
|
|
2022
Q3 | $3.39M | Buy |
513,293
+34,768
| +7% | +$230K | ﹤0.01% | 676 |
|
|
2022
Q2 | $2.5M | Sell |
478,525
-3,594
| -0.7% | -$18.8K | ﹤0.01% | 698 |
|
|
2022
Q1 | $3.33M | Buy |
482,119
+13,322
| +3% | +$91.9K | ﹤0.01% | 708 |
|
|
2021
Q4 | $5.84M | Sell |
468,797
-3,449
| -0.7% | -$42.9K | ﹤0.01% | 693 |
|
|
2021
Q3 | $14.8M | Buy |
472,246
+97,080
| +26% | +$3.03M | ﹤0.01% | 641 |
|
|
2021
Q2 | $10.7M | Buy |
375,166
+94,002
| +33% | +$2.69M | ﹤0.01% | 669 |
|
|
2021
Q1 | $12.2M | Sell |
281,164
-3,023
| -1% | -$131K | ﹤0.01% | 651 |
|
|
2020
Q4 | $20.3M | Sell |
284,187
-233,824
| -45% | -$16.7M | 0.01% | 591 |
|
|
2020
Q3 | $15.6M | Buy |
+518,011
| New | +$15.6M | 0.01% | 590 |
|